An approved anti-cancer drug successfully targets the first step in the toxic chain reaction that leads to Alzheimer’s disease, suggesting that treatments may be found to lower the risk of developing the neurodegenerative condition.
Researchers have identified how proteins that play a key role in Alzheimer’s disease are linked in a pathway that controls its progression, and that drugs targeting this pathway may be a potential new way of treating the disease.
Alzheimer’s Research UK, the world’s largest dedicated dementia research charity, has announced a £30 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of Cambridge, Oxford and UCL (University College London). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.
New research using fruit flies with Alzheimer’s protein finds that the disease doesn’t stop the biological clock ticking, but detaches it from the sleep-wake cycle that it usually regulates. Findings could lead to more effective ways to improve sleep patterns in those with Alzheimer’s.
Researchers have shown that tiny quantities of the protein tau can be enough to kick-start an aggregation process which may explain the onset of Alzheimer’s in the brain.
New research establishes nature of malfunction in protein molecules that can lead to onset of dementia.